Broad Institute of MIT and Harvard shared a post on LinkedIn:
“Cell-free DNA (cfDNA) collected from blood plasma provides a view into cancers’ genomic landscape, variety, and evolution throughout the body, especially for metastatic cancers.
Writing in Nature Communications, Ignaty Leshchiner, Arielle Medford, Justin C., Gaddy Getz, UCLA’s Aditya Bardia, and collaborators at Massachusetts General Hospital and Guardant Health describe their work studying cfDNA from more than 12,800 patients with metastatic breast cancer, sequenced using the Guardant360 platform, which includes 74 clinically significant genes. Using an ML random forest model, they classified patients into subtypes correlating with therapeutic opportunities, resistance mechanisms, and other features.
The dataset also reveals clonal co-behaviors, and could be a valuable resource for clinical investigation and trial design.”
Title: Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer
Authors: Ignaty Leshchiner, Arielle J. Medford, Justin Cha, Lesli A. Kiedrowski, Andrzej Niemierko, Jennifer C. Keenan, Charles S. Dai, Laura M. Spring, Beverly Moy, Seth A. Wander, Neelima Vidula, Steven J. Isakoff, Dejan Juric, Mendy Miller, Andrew A. Davis, Lorenzo Gerratana, Ami Shah, Ben H. Park, Adam Brufsky, Joyce O’Shaughnessy, Rebecca J. Nagy, Leif W. Ellisen, Massimo Cristofanilli, Aditya Bardia, Gad Getz
Read the Full Article on Nature Communications
You can also read: FDA Approves Tucatinib as Front-Line Maintenance in HER2-Positive Metastatic Breast Cancer
